Log in
LON:TRX

Tissue Regenix Group Share Forecast, Price & News

GBX 0.34
+0.01 (+3.03 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
0.33
Now: GBX 0.34
0.35
50-Day Range
0.30
MA: GBX 0.33
0.37
52-Week Range
0.28
Now: GBX 0.34
3.50
Volume7.34 million shs
Average Volume36.99 million shs
Market Capitalization£23.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and Cardiac divisions. The company's decellularisation (dCELL) technology removes DNA and other cellular material from animal and human tissue leaving intact an inert acellular matrix upon which the patient's cells can repopulate. Its dCELL technology has applications in various clinical needs, such as wound care, and heart valve replacement. It offers DermaPure used for the treatment and management of complex and chronic wounds; and SurgiPure XD for the repair of hernias and/or body wall defects, which require the use of reinforcing or buttressing material to obtain the desired surgical outcome. The company is also developing OrthoPure XM, which makes the implant biocompatible and provides a biomechanically appropriate scaffold for cellular repopulation and eventual regeneration in the partial meniscectomy; OrthoPure XT and OrthoPure HT used for the anterior cruciate ligament injuries; and CardioPure for the replacement of human aortic and pulmonary valves. Tissue Regenix Group plc was incorporated in 2006 and is based in Leeds, the United Kingdom.
Read More
Tissue Regenix Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.67 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1904-567609

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£13.05 million
Cash FlowGBX 0.20 per share
Book ValueGBX 0.50 per share

Profitability

Miscellaneous

Employees100
Outstanding Shares7,032,990,208
Market Cap£23.91 million
Next Earnings DateN/A
OptionableOptionable
GBX 0.34
+0.01 (+3.03 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRX News and Ratings via Email

Sign-up to receive the latest news and ratings for TRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tissue Regenix Group (LON:TRX) Frequently Asked Questions

How has Tissue Regenix Group's stock price been impacted by Coronavirus (COVID-19)?

Tissue Regenix Group's stock was trading at GBX 0.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TRX shares have decreased by 58.8% and is now trading at GBX 0.34.
View which stocks have been most impacted by COVID-19
.

How were Tissue Regenix Group's earnings last quarter?

Tissue Regenix Group PLC (LON:TRX) posted its earnings results on Wednesday, September, 2nd. The company reported ($0.16) earnings per share for the quarter.
View Tissue Regenix Group's earnings history
.

Who are some of Tissue Regenix Group's key competitors?

What other stocks do shareholders of Tissue Regenix Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tissue Regenix Group investors own include Argos Therapeutics (ARGSQ), TransEnterix (TRXC), Swedbank (SWDBY), Trevena (TRVN), Allied Minds (ALM), ArQule (ARQL), CIRCOR International (CIR), WisdomTree Middle East Dividend Fund (GULF), W W Grainger (GWW) and Just Energy Group (JE).

Who are Tissue Regenix Group's key executives?

Tissue Regenix Group's management team includes the following people:
  • Mr. Steven Couldwell, CEO & Director (leave of Absence) (Age 58)
  • Mr. Gareth Hywel Jones, CFO, Company Sec. & Exec. Director (Age 50)
  • Mr. Mike Izon, Technical Director
  • Caitlin Pearson, Head of Communications
  • Mr. Joel Pickering, Pres of Tissue Regenix Wound Care Inc

What is Tissue Regenix Group's stock symbol?

Tissue Regenix Group trades on the London Stock Exchange (LON) under the ticker symbol "TRX."

How do I buy shares of Tissue Regenix Group?

Shares of TRX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tissue Regenix Group's stock price today?

One share of TRX stock can currently be purchased for approximately GBX 0.34.

How big of a company is Tissue Regenix Group?

Tissue Regenix Group has a market capitalization of £23.91 million and generates £13.05 million in revenue each year. Tissue Regenix Group employs 100 workers across the globe.

What is Tissue Regenix Group's official website?

The official website for Tissue Regenix Group is www.tissueregenix.com.

How can I contact Tissue Regenix Group?

Tissue Regenix Group's mailing address is Innovation Way, YORK, YO10 5NY, United Kingdom. The company can be reached via phone at +44-1904-567609.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.